

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

AZRIA, MOISE ET AL.

APPLICATION NO: 10/565455

FILED: APRIL 5, 2006

FOR: USE OF CALCITONIN IN OSTEOARTHRITIS

ART UNIT: 1646

EXAMINER: XIE, XIAOZHEN

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed May 7, 2007.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9308

Date:

7/27/09

Respectfully submitted,



Leslie Fischer
Attorney for Applicant
Reg. No. 58,393